スタディの結果、将来の虚血リスクを示唆する臨床上の因子が同定された

REACH:スタディの結果、アテローム血栓症患者の様々な心血管イベントのリスクファクターが同定された
REACH: Study identifies a variety of risk factors for cardiovascular events in patients with atherothrombosis
冠動脈疾患、末梢動脈疾患、脳血管疾患、または複数の既知のリスクファクターを有する外来患者45,000人以上のREACH(Reduction of Atherothrombosis for Continued Health:健康を維持するためのアテローム血栓症の軽減)レジストリのフォローアップデータから、将来の虚血性疾患のリスクが容易に見極められることが示された。この報告は2010年European Society of Cardiology学会で発表され、JAMA 9月22日号に掲載された。高血圧および高コレステロール血症は、それぞれ81.3%および70.4%の患者が有していた。Polyvascular diseaseは15.9%の患者において認められ、48.4%が虚血性イベントの既往を有していた(28.1%が過去1年以内)。経過観察期間中に5,481人に心血管イベントが発現した。アテローム血栓症を有する患者のうちその後に虚血性イベントを発現したのは、ベースライン時点で虚血イベントの既往を有していた患者21.890人において最も高率であった(18.3%)。安定した冠動脈、脳血管、または末梢動脈疾患を有する患者のリスクは低く(12.2%)、リスクファクターは有するが確立されたアテローム血栓症を有さない患者のリスクは9.1%であった(それぞれの比較においていずれもP<0.001)。地理的にみて、東欧および中東の人々はリスクが最も高く、日本人はリスクが平均より低かった。
Full Text

Clinical descriptors can assist clinicians in identifying patients with various stages of atherothrombosis (abnormal fatty deposits in an artery) who are at high-risk of future cardiovascular events, according to a study that appears in the September 22 issue of JAMA. The study was released early online to coincide with its presentation at the European Society of Cardiology meeting in Stockholm.

"Patients with atherothrombosis are at elevated risk of ischemic events but, depending on their specific manifestations of atherothrombosis, may have varying degrees of future risk for ischemic events," the authors write as background in the article. "For clinicians, the ability to identify rapidly the major determinants of risk among patients with atherosclerosis would be useful to triage novel preventive therapies toward those at the higher end of the spectrum."

Deepak L. Bhatt, M.D., M.P.H., of the VA Boston Healthcare System, Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues studied 45,227 patients who were enrolled in the global Reduction of Atherothrombosis for Continued Health (REACH) study. Detailed information was gathered at baseline, with additional annual follow-up at one, two, three and four years. Patients were enrolled between 2003 and 2004 and follow-up continued until 2008.

Hypertension and hypercholesterolemia were common, present in 81.3 percent and 70.4 percent of patients, respectively. Polyvascular disease was present in 15.9 percent of patients and 48.4 percent had prior ischemic events, with 28.1 percent of those having an ischemic event within the previous year.

During the follow-up period, 5,481 patients experienced cardiovascular events including 2,315 with cardiovascular death, 1,228 with myocardial infarction 1,898 with stroke and 40 with both a myocardial infarction and stroke occurring on the same day. Among patients with atherothrombosis, the 21 890 patients with a prior history of ischemic events at baseline had the highest rate of subsequent ischemic events (18.3%). The 15,264 patients with stable coronary, cerebrovascular, or peripheral artery disease had a lower risk (12.2%), and the 8073 patients with risk factors but no established atherothrombosis had only a 9.1% risk (p<.001 for all comparisons).

Geographically, people in Eastern Europe and the Middle East were at the highest risk, while Japanese patients had lower-than-average risk.

"Among all categories of patients, diabetes substantially increased the risk of future ischemic events," the authors write. "In those with established atherothrombosis, polyvascular disease was a particularly strong independent risk factor, even stronger than diabetes." Additionally, the authors conclude that, "this analysis of a contemporary, international cohort of patients at various stages of atherothrombosis shows that there is a whole spectrum of ischemic risk in patients with risk factors or with established cardiovascular disease and that easily ascertainable clinical characteristics are the prominent factors associated with a high risk of future ischemic events."